# Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemoth

Source: https://onco.cc/trials/nct06616584/  
OnCo record `nct06616584` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of cemiplimab, dexamethasone, docetaxel and ramucirumab in lung cancer, run by SWOG Cancer Research Network, now recruiting.

## Summary

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) is a phase 2/3, randomised interventional study registered as NCT06616584 by SWOG Cancer Research Network, with a registry enrolment figure of 378 participants, started 2025-05-22 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biospecimen Collection; Cemiplimab; Computed Tomography; Dexamethasone; Docetaxel; Magnetic Resonance Imaging; Ramucirumab. Conditions listed: Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8. Primary outcome: Overall survival (OS). Lung eligibility wording from the registry: "Assignment to S1800E is determined by the LUNGMAP protocol". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-25
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT06616584
- Phase: 2/3
- Setting: A Randomized Phase II/III Study of Docetaxel and Ramucirumab With or Without Cemiplimab for Participants Previously Treated With Platinum-Based Chemotherapy and Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study)
- Sponsor: SWOG Cancer Research Network
- Enrolled: 378

## Sources

- ClinicalTrials.gov NCT06616584: https://clinicaltrials.gov/study/NCT06616584

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [Anti-angiogenic therapy](https://onco.cc/technologies/antiangiogenic/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [Monoclonal antibodies](https://onco.cc/technologies/monoclonal-antibody/)
- drugs: [Cemiplimab](https://onco.cc/drugs/cemiplimab/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Ramucirumab](https://onco.cc/drugs/ramucirumab/)
- companies: [Regeneron](https://onco.cc/companies/regeneron/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct06616584.json